Turn Therapeutics Inc.

NASDAQ:TTRX

Biotechnology

Healthcare
$8.89 -2.79%

-$0.17 today

Market cap
$271.79M
Beta
2.77
P/E (TTM)
-45.0
EPS (TTM)
-$0.13
52W Low $2.57High $26.50

Volume 0.05M

Average 0.04M

TTRX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Turn Therapeutics Inc.NASDAQ: TTRX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares of 29.48M shares in Q1 FY2026

Q1 FY2026 weighted avg shares was 29.48M shares. Trailing-twelve-month weighted avg shares was 25.17M shares.

Context

  • Weighted avg shares increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly weighted avg shares holds near 29.48M shares or moves back toward the trailing-twelve-month quarterly average of 6.29M shares.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
29.48M+0.1% QoQ
Last fiscal yearDec 2025
13.74M+2.4% YoY
LTMMar 2026
25.17M— YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+2.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
13.74M USD
Year-over-year change
+2.4%
2-year CAGR
+1.9%

Weighted Avg Shares vs competitors

How TTRX compares with its peers on the latest reported figures

  • TTRX's LTM Mar 2026 weighted avg shares of 25.17M shares is the 8th highest of the 9 companies compared; the peer median is 53.88M shares.
TTRX Competitors Peer median
Weighted Avg Shares for TTRX and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+214.9%
IKTInhibikase Therapeutics, Inc.LTM Mar 202694.17M +114.9%+186.0%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
HURATuHURA Biosciences, Inc.LTM Mar 202650.79M +127.0%+911.7%
AGENAgenus Inc.LTM Mar 202633.32M +48.8%+28.3%
ANIXAnixa Biosciences, Inc.LTM Apr 202632.94M +2.7%+2.2%
TTRXTurn Therapeutics Inc.LTM Mar 202625.17M ——
GLSIGreenwich LifeSciences, Inc.LTM Mar 202613.8M +5.4%+1.6%
Peer median (excluding TTRX) 53.88M+59.1%+32.1%

Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development7.5K245.96K265.57K
Selling, General & Admin2.3M1.55M5.59M
Operating Expenses2.31M1.8M5.86M
Depreciation & Amortization43.92K47.48K52.75K
EBITDA(2.25M)(1.72M)(3.14M)
EBITDA Margin———
Operating Income(2.31M)(1.8M)(5.86M)
Operating Margin———
Interest Income15.88K28.71K29.58K
Interest Expense000
Other Income / Expenses15.88K28.71K2.66M
Income Before Tax(2.29M)(1.77M)(3.19M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(2.29M)(1.77M)(3.19M)
Net Margin———
EPS (Basic)(0.17)(0.13)(0.23)
EPS (Diluted)(0.17)(0.13)(0.23)
Weighted Avg Shares13.25M13.42M13.74M
Weighted Avg Shares (Diluted)13.25M13.42M13.74M

Turn Therapeutics Inc.

NASDAQ:TTRX

Intrinsic Alpha fair value

Locked

Current Price

$8.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.